Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL13622863 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL15590870 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL759366 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL12929005 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL18389589 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL10122072 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13241436 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321177-A1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | AVETA BIOMICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| US-9913822-B2 | Combination therapy with an anti-hyaluronan agent and therapeutic agent | HALOZYME, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-20170290796-A1 | COMBINATION THERAPY WITH AN ANTI-HYALURONAN AGENT AND THERAPEUTIC AGENT | HALOZYME, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170042818-A1 | LUNG TARGETING DUAL DRUG DELIVERY SYSTEM | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-02-16 | — | — | US | disclosed |
| US-9556156-B2 | Compounds, their synthesis and their uses | Sphaera Pharma Pte Ltd. (SG) | 2017-01-31 | — | — | US | disclosed |
| US-9364588-B2 | Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20080214847-A1 | By column chromatography on silica gel using a solvent mixture containing methyl isobutyl ketone and a less polar solvent as the mobile phase; large scale purification | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2008-09-04 | — | — | US | disclosed |
| US-20080214847-A1 | By column chromatography on silica gel using a solvent mixture containing methyl isobutyl ketone and a less polar solvent as the mobile phase; large scale purification | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2008-09-04 | — | — | US | disclosed |
| US-20080206808-A1 | GALACTOSYL NUCLEOTIDE SUGAR | NEOSE TECHNOLOGIES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-7265084-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7226903-B2 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226903-B2 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070092922-A1 | Taxol immunoassay | SALADAX BIOMEDICAL INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7175993-B2 | Taxol immunoassay | SALADAX BIOMEDICAL, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | INNOVATIONAL HOLDINGS LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206808-A1 | GALACTOSYL NUCLEOTIDE SUGAR | GALNT1, UGCG, GALNT3 | TUBB4A 3540/4885TUBB 2807/4885TUBA3C 3794/4885 |
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | TUBB8B, TUBA1B, TUBB | TUBB4A 17/4885TUBB 3/4885TUBA3C 20/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | TUBB4A 237/4885TUBB 461/4885TUBA3C 625/4885 |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | EPOR, HBG2, HAMP | TUBB4A 3034/4885TUBB 2595/4885TUBA3C 3639/4885 |
| US-20170290796-A1 | COMBINATION THERAPY WITH AN ANTI-HYALURONAN AGENT AND THERAPEUTIC AGENT | CD44, ENGASE, HPSE | TUBB4A 408/4885TUBB 381/4885TUBA3C 785/4885 |
| US-20080214847-A1 | By column chromatography on silica gel using a solvent mixture containing methyl isobutyl ketone and a less polar solvent as the mobile phase; large scale purification | AURKB, KIFC1, CCNB3 | TUBB4A 39/4885TUBB 24/4885TUBA3C 49/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TUBB4A 237/4885TUBB 461/4885TUBA3C 625/4885 |
| US-20070092922-A1 | Taxol immunoassay | TUBB6, TUBA1C, TUBB1 | TUBB4A 10/4885TUBB 7/4885TUBA3C 18/4885 |
| US-20230321177-A1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | PCBP1, CYP3A5, ABCB1 | TUBB4A 3413/4885TUBB 2943/4885TUBA3C 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.